First Real-World Study of Eptinezumab (CGRP Antibody) in Asian Migraine Patients | Research

The takeaway

Real-world prospective study shows eptinezumab is effective and well-tolerated in Asian migraine patients, providing the first evidence for this CGRP antibody in non-Western populations.

First Asian real-world data
Eptinezumab shown effective and tolerable in Asian migraine patients, extending evidence beyond Western trial populations

What the researchers found

Eptinezumab was effective and well-tolerated in Asian migraine patients in real-world clinical practice, with significant improvements in migraine frequency, intensity, and disability.

Why it matters

Asian populations represent a large proportion of global migraine sufferers but have been underrepresented in CGRP antibody trials. This first real-world evidence in Asian patients fills a critical knowledge gap and supports treatment access.

The numbers in context

Prospective real-world study in Asian migraine patients; outcomes aligned with pivotal phase 3 trial efficacy data.

How the study worked

Prospective, real-world observational study of eptinezumab in Asian migraine patients. Assessed migraine days, headache intensity, disability scores, and tolerability.

Who was studied

Asian patients with migraine receiving eptinezumab in real-world clinical practice

What this study cannot tell us

Observational study without a control group. Real-world data may reflect selection bias. Short follow-up may not capture long-term outcomes. Sample size and specific Asian populations not detailed in this preview.

How to read the evidence

Moderate evidence: prospective real-world study in a new population, but observational design without control group.

When this study was published

Published in 2024. First real-world eptinezumab data in Asian migraine patients.

The bigger picture

As CGRP-targeting migraine drugs expand globally, real-world evidence in diverse populations is essential. This study supports that eptinezumab's clinical trial benefits translate to Asian clinical practice, building the evidence base for broader global adoption.

Questions still open

Does eptinezumab work differently in specific Asian ethnic groups?
How does eptinezumab IV dosing compare to monthly SC injection of other CGRP antibodies in Asian patients?
Are there pharmacogenomic factors that affect CGRP antibody response in Asian populations?

Common questions

Does eptinezumab work for Asian migraine patients?

Yes — this first real-world study in Asian patients shows eptinezumab effectively reduced migraine frequency, headache intensity, and disability with good tolerability, consistent with results in Western populations.

How is eptinezumab different from other CGRP drugs?

Eptinezumab is the only CGRP antibody given by IV infusion (every 3 months), while others (erenumab, fremanezumab, galcanezumab) are self-injected subcutaneously. The IV route may provide faster onset and is convenient for patients who prefer fewer treatments.

Read the original research

A real-world prospective observational study of eptinezumab in Asian patients with migraine.

Headache, 64(7), 810-824

View on PubMed ↗Publisher’s paper ↗

Citation

Zhao, Yi Jing; Ong, Jonathan Jia Yuan; Sonu, Sumit Kumar; Dang, Jiaojiao; Ng, Chai Ching; Herr, Keira Joann; Bose, Rohini; Jion, Yasmin Idu. (2024). A real-world prospective observational study of eptinezumab in Asian patients with migraine.. Headache, 64(7), 810-824. https://doi.org/10.1111/head.14737